Page 1219 - Williams Hematology ( PDFDrive )

1194 Part IX: Lymphocytes and Plasma Cells

48. Gazzinelli RT, Hieny S, Wynn TA, et al: Interleukin 12 is required for the T-lympho- 65. Haliotis T, Roder J, Klein M, et al: Chediak-Higashi gene in humans. I. Impairment of
cyte-independent induction of interferon gamma by an intracellular parasite and natural-killer function. J Exp Med 151:1039–1048, 1980.
induces resistance in T-cell-deficient hosts [see comments]. Proc Natl Acad Sci U S A 66. Kanavaros P, Lescs MC, Briere J, et al: Nasal T-cell lymphoma: A clinicopathologic
90:6115–6119, 1993. entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81:2688–
49. Mond JJ, Brunswick M: A role for IFN-gamma and NK cells in immune response to T 2695, 1993.
cell-regulated antigens types 1 and 2. Immunol Rev 99:105–118, 1987. 67. Liang X, Graham DK: Natural killer cell neoplasms. Cancer 112:1425–1436, 2008.
50. Yuan D, Wilder J, Dang T, et al: Activation of B lymphocytes by NK cells. Int Immunol 68. Reynolds CW, Foon KA: Tgamma-lymphoproliferative disorders in man and experi-
4:1373–1380, 1992. mental animals: A review of the clinical, cellular and functional characteristics. Blood
51. Goldszmid RS, Bafica A, Jankovic D, et al: TAP-1 indirectly regulates CD4+ T cell prim- 64:1146–1158, 1984.
ing in Toxoplasma gondii infection by controlling NK cell IFN-gamma production. J 69. Bachanova V, Cooley S, Defor TE, et al: Clearance of acute myeloid leukemia by hap-
Exp Med 204:2591–2602, 2007. loidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
52. Scharton TM, Scott P: Natural killer cells are a source of interferon gamma that drives Blood 123:3855–3863, 2014.
differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major 70. Korde N, Carlsten M, Lee MJ, et al: A phase II trial of pan-KIR2D blockade with
of mice. J Exp Med 178:567–577, 1993. IPH2101 in smoldering multiple myeloma. Haematologica 99:e81–e83, 2014.
53. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immu- 71. Furutani E, Smith A, Uchida N, et al: SiRNA inactivation of the inhibitory recep-
nity. Nat Rev Immunol 3:133–146, 2003. tor NKG2A augments the anti-tumor effects of adoptively transferred NK cells in
54. Goldszmid Romina S, Caspar P, Rivollier A, et al: NK cell-derived interferon-γ orches- tumor-bearing hosts. ASH Annu Meet Abstr 1015, 2010.
trates cellular dynamics and the differentiation of monocytes into dendritic cells at the 72. Childs RW, Berg M: Bringing natural killer cells to the clinic: Ex vivo manipulation.
site of infection. Immunity 36:1047–1059, 2012. Hematology Am Soc Hematol Educ Program 2013:234–246, 2013.
55. Gerosa F, Gobbi A, Zorzi P, et al: The reciprocal interaction of NK cells with plasmacy- 73. Berg M, Lundqvist A, McCoy P Jr, et al: Clinical-grade ex vivo-expanded human nat-
toid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol ural killer cells up-regulate activating receptors and death receptor ligands and have
174:727–734, 2005. enhanced cytolytic activity against tumor cells. Cytotherapy 11:341–355, 2009.
56. Moretta A: Natural killer cells and dendritic cells: Rendezvous in abused tissues. Nat 74. Zhu D, Corral LG, Fleming YW, et al: Immunomodulatory drugs Revlimid (R) (lenalid-
Rev Immunol 2:957–964, 2002. omide) and CC-4047 induce apoptosis of both hematological and solid tumor cells
57. Trinchieri G: Natural killer cells in hematopoiesis, in The Natural Immune System: Natural through NK cell activation. Cancer Immunol Immunother 57:1849–1859, 2008.
Killer Cells edited by Lewis CE and James O’D. IRL Press at Oxford University Press, 75. Benson DM Jr, Bakan CE, Mishra A, et al: The PD-1/PD-L1 axis modulates the natu-
Oxford, New York, pp 41–65. 1992. ral killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel
58. Murphy WJ, Keller JR, Harrison CL, et al: Interleukin-2-activated natural killer cells monoclonal anti-PD-1 antibody. Blood 116:2286–2294, 2010.
can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 76. Somanchi SS, Somanchi A, Cooper LJ, et al: Engineering lymph node homing of ex
80:670–677, 1992. vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor
59. Cudkowicz G, Hochman PS: Do natural killer cells engage in regulated reaction against CCR7. Blood 119:5164–5172, 2012.
self to ensure homeostasis? Immunol Rev 44:13–41, 1979. 77. Sackstein R: The lymphocyte homing receptors: Gatekeepers of the multistep paradigm.
60. Randrup-Thomsen A, Pisa P, Bro-Jorgensen K, et al: Mechanisms of lymphocytic cho- Curr Opin Hematol 12:444–450, 2005.
riomeningitis virus-induced hemopoietic dysfunction. J Virol 59:428–433, 1986. 78. Srivastava S, Lundqvist A, Childs RW: Natural killer cell immunotherapy for cancer: A
61. Velardi A: Natural killer cell alloreactivity 10 years later. Curr Opin Hematol 19:421– new hope. Cytotherapy 10:775–783, 2008.
426, 2012. 79. Lundqvist A, Yokoyama H, Smith A, et al: Bortezomib treatment and regulatory
62. Velardi A, Ruggeri L, Alessandro, et al: NK cells: A lesson from mismatched hematopoi- T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood
etic transplantation. Trends Immunol 23:438–444, 2002. 113:6120–6127, 2009.
63. Vesely MD, Kershaw MH, Schreiber RD, et al: Natural innate and adaptive immunity to 80. Boissel L, Betancur M, Lu W, et al: Comparison of mRNA and lentiviral based transfec-
cancer. Annu Rev Immunol 29:235–271, 2011. tion of natural killer cells with chimeric antigen receptors recognizing lymphoid anti-
64. Jost S, Altfeld M: Control of human viral infections by natural killer cells. Annu Rev gens. Leuk Lymphoma 53:958–965, 2012.
Immunol 31:163–194, 2013.

Kaushansky_chapter 77_p1189-1194.indd 1194 9/21/15 11:23 AM